



1814

PATENT
Atty Dkt: 203442102500

Ap. 1814

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on JULY 7, 1995

7/7/95
Date

Alan Shimpie
Signature

#5
1.9.0
9/5/95

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

VISHVA M. DIXIT

Serial No.: 08/404,832

Group Art Unit: Unknown

Filing Date: March 13, 1995

Examiner: Unassigned

Title: CD40 BINDING COMPOSITIONS
AND METHODS OF USING SAME

INFORMATION DISCLOSURE

STATEMENT UNDER 37 CFR § 1.97

Assistant Commissioner
for Patents
Washington, D.C. 20231

RECEIVED
AUG 01 1995
GROUP 1800

Dear Sir:

The information listed below, which may be material to the examination of the above-identified application, was disclosed to the Examiner throughout the application as originally filed. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. The information includes:

Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" EMBO J. (1989) 8:1403-1410.

Inui et al., "Identification of the intracytoplasmic region essential for signal transduction through a B cell activation molecule, CD40" Eur. J. Immunol. (1990) 20:1747-1753.

Armitage et al., "Molecular and biological characterization of a murine ligand for CD40" Nature (1992) 357:80-82.

Banchereau et al., "Long-term human B cell lines dependent on interleukin-4 and antibody to CD40" Science (1991) 251:70-72.

Liu et al., "Mechanism of antigen-driven selection in germinal centres" Nature (1989) 342:929-931.

Zhang et al., "CD40 stimulation provides an IFN- γ -independent and IL-4-dependent differentiation signal directly to human B cells for IgE production" J. Immunol. (1991) 146:1836-1842.

Allen et al., "CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome" Science (1993) 259:990-993.

Korthäuer et al., "Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM" Nature (1993) 361:539-541.

Fuleihan et al., "Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM" Proc. Natl. Acad. Sci. USA (1993) 90:2170-2173.

Ochs et al., "Advances in X-linked immunodeficiency diseases" Curr. Opin. Pediatr. (1993) 5:684-691.

Caux et al., "Activation of human dendritic cells through CD40 cross-linking" J. Exp. Med. (1994) 180:1263-1272.

Werner-Favre et al., "Similar CD40 ligand expression on EL-4 thymoma cell lines with widely different helper activity for B lymphocytes" Immunol. (1994) 81:111-114.

Correll et al., "Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells" Proc. Natl. Acad. Sci. USA (1989) 86:8912-8916.

Bordignon et al., "Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells" Proc. Natl. Acad. Sci. USA (1989) 86:6748-6752.

Culver, "Lymphocytes as cellular vehicles for gene therapy in mouse and man" Proc. Natl. Acad. Sci. USA (1991) 88:3155-3159.

Rill et al., "An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer" Blood (1992) 79:2694-2700.

Anderson, "Human gene therapy" Science (1992) 256:808-813.

PATENT
USSN 08/404,832
Atty Dkt 203442102500

Spira et al., "The identification of monoclonal class switch variants by sib selection and an ELISA assay" J. Immunol. Meth. (1984) 74:307-315.

Oi et al., "Chimeric antibodies" BioTechniques (1986) 4:214-221.

Herlyn et al., "Anti-idiotypic antibodies bear the internal image of a human tumor antigen" Science (1986) 232:100-102.

Armitage et al., "CD40 ligand is a T cell growth factor" Eur. J. Immunol. (1993) 23:2326-2331.

Torres et al., "Differential increase of an alternatively polyadenylated mRNA species of murine CD40 upon B lymphocyte activation" J. Immunol. (1992) 148:620-626.

International (PCT) Patent Publication No. WO 93/08207 (04/29/93).

International (PCT) Patent Publication No. WO 94/04570 (03/03/94).

European Patent Application No. 0555880 (08/18/93).

European Patent Application No. 0585943 (03/09/94).

Harper et al., "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases" Cell (1993) 75:805-816.

Staudinger et al., "Interactions among vertebrate helix-loop-helix proteins in yeast using the two-hybrid system" J. Biol. Chem. (1993) 268:4608-4611.

Ron et al., "pGStag - a versatile bacterial expression plasmid for enzymatic labeling of recombinant proteins" BioTechniques (1992) 13:866-869.

Studier, "Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system" J. Mol. Biol. (1991) 219:37-44.

Higuchi et al., "A general method of *in vitro* preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions" Nucl. Acids Res. (1988) 16:7351-7367.

O'Rourke et al., "Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers" J. Biol. Chem. (1992) 267:24921-24924.

Lupas et al., "Predicting coiled coils from protein sequences" Science (1991) 252:1162-1164.

Altschul et al., "Issues in searching molecular sequence databases" Nature Genet. (1994) 6:119-129.

Yang et al., "A protein kinase substrate identified by the two-hybrid system" Science (1992) 257:680-682.

Hu et al., "A novel RING finger protein interacts with the cytoplasmic domain of the CD40" J. Biol. Chem. (1994) 269:30069-30072.

PATENT
USSN 08/404,832
Atty Dkt 203442102500

The references above are summarized throughout the application as originally filed. The summaries contain what the undersigned believes to be the salient aspects of the cited references. They are not intended to be a comprehensive statement of the relevance of the references to the subject invention.

This Information Disclosure Statement is submitted before receipt of the first Office Action on Merits. Therefore, the applicants believe that no fee is due. However, the Commissioner is hereby authorized to charge any fees which may be required by this paper to Deposit Account Number 03-1952.

Applicants would appreciate the Examiner's initialling and returning the Form PTO-1449, indicating that the references have indeed been considered and made of record herein.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or

PATENT
USSN 08/404,832,
Atty Dkt 203442102500

(iv) the above information constitutes prior art to the
subject invention.

Respectfully submitted,

By Antoinette F. Konski
Antoinette F. Konski
Registration No. 34,202

Date: July 6, 1995

MORRISON & FOERSTER
755 Page Mill Road
Palo Alto, CA 94304-1018
(415) 813-5600
Fax: (415) 494-0792